查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1754225

口乾症（口乾症）治療市場規模、佔有率、趨勢及預測（按類型、藥物類型、配銷通路和地區），2025 年至 2033 年

Xerostomia (Dry Mouth Disease) Therapeutics Market Size, Share, Trends and Forecast by Type, Drug Type, Distribution Channel, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球口乾症（口乾症）治療市場規模達7.6303億美元。展望未來， IMARC Group估計，到2033年，該市場規模將達到10.0731億美元，2025年至2033年的複合年成長率為2.98%。北美目前佔據市場主導地位，2024年的市場佔有率將超過36.8%，這得益於其完善的醫療保健系統、對疾病認知的加深，以及老年人口和藥物治療導致的口乾症發病率上升。

隨著乾燥症、糖尿病以及癌症患者的放射治療等口乾症發生率的上升，口乾症（口乾症）治療市場不斷擴張。隨著肺癌和人口老化，對有效治療的需求顯著成長。此外，醫療保健專業人員和患者對口乾症的認知也日益加深，促使他們尋求治療方案。此外，包括促泌劑和唾液替代品在內的改良藥物配方，由於這些新配方能夠為患者提供更佳的療效和更舒適的體驗，也推動了市場的發展。藥物輸送系統的技術進步，尤其是對個人化醫療的重視，也促進了市場的成長。

在美國，口乾症治療市場正在成長，因為老化、糖尿病和癌症治療（尤其是頭部和頸部放射治療）等風險因素的發生率很高。標靶療法的日益普及以及非處方產品的技術進步，為患者提供了更多治療選擇。例如，根據產業報告顯示，威斯康辛大學醫學院公共衛生學院的研究人員正與PACT合作進行一項臨床試驗，探索利用患者自身增強幹細胞改善乾燥症唾液腺功能的可能性。這種創新方法包括從患者骨髓中提取幹細胞，激活它們，然後將其注射到唾液腺中。此外，隨著對口乾症對健康影響的認知不斷加深，預計美國對有效且便捷的治療方法的需求將穩步成長。

口乾症（口乾症）治療市場趨勢：

唾液促效劑配方的進展

口乾症治療市場在唾液促效劑的配方方面取得了一些最重要的進展。然而，對長期有效治療的需求正在推動這些變化。大多數傳統的唾液替代品只能提供暫時的緩解，迫使研究人員尋求更新或創新的藥物傳遞方法，例如黏膜黏附劑、緩釋凝膠和基於奈米顆粒的療法。各公司也將注意力轉向植物衍生化合物或再生醫學方法，以刺激而非取代這種天然的唾液分泌能力。針對唾液腺功能的生物製劑（例如生長因子和基因療法）正在開發中，這些生物製劑可能會帶來一些長期益處。這種進展透過改善保濕性和減少重複使用頻率，提高了患者的依從性和治療效果。具有更高生物利用度的處方製劑進一步促進了市場的成長。一篇研究文章指出，超過30%的65歲及以上人群患有口乾症，因此對能夠提高患者依從性並提供持續緩解的創新解決方案的需求日益成長。因此，業界正從緩解症狀的產品轉向針對口乾病因的治療介入。這將確保患者獲得更好的治療效果。

處方藥療法的接受度日益高於非處方藥

隨著醫療專業人員的認知度不斷提高，以及患者對全面長期管理的關注，口乾症治療市場正從非處方口乾緩解產品轉向處方藥。人工唾液噴霧劑、含片或漱口水等非處方產品僅能緩解症狀，卻未能解決口乾的根本原因。另一方面，處方藥，如毛果芸香鹼和西維美林，毒蕈鹼受體激動劑，能夠刺激唾液腺功能，產生持久療效。此外，一些有前景的臨床開發候選藥物能夠促進唾液分泌和腺體再生，這使得處方治療成為更可行的選擇。醫療保健提供者擴大向因乾燥綜合症、放射治療或多種藥物引起的口乾而繼發慢性口乾症的患者推薦處方治療。隨著製藥公司持續投資開發療效和安全性更高的標靶治療藥物，這種轉變預計將推動市場成長。研究表明，高達73.4%接受化療的患者報告出現口乾症，而接受頭頸癌放射治療的患者中，口乾症的盛行率則高達90%。這一趨勢推動了針對潛在病理的處方治療的普及。

慢性疾病和藥物導致口乾症盛行率上升

口乾症發生率上升的主要原因是慢性疾病的增加以及藥物副作用。糖尿病、乾燥症和其他自體免疫疾病等疾病會直接影響唾液腺，導致口乾症症狀持續很長時間。同樣，透過放射線治療和化學治療進行的癌症治療通常會損害唾液腺，導致口乾症成為癌症患者的常見副作用。研究表明，口乾症影響著13-17%的一般人群，由於多種藥物合併使用，老年人的盛行率甚至高達30-40%。抗高血壓藥、抗憂鬱藥和鴉片類藥物等藥物的廣泛使用進一步加劇了口乾症的發生率，已知有超過400種常用處方藥會導致口乾副作用。隨著全球老化和慢性病負擔的不斷加重，對有效治療口乾症藥物的需求將會增加。因此，製藥公司正在研發能夠緩解口乾症狀並解決其根本原因的藥物。因此，患者數量的成長代表著口乾症治療市場創新和成長的重要領域。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球口乾症（口乾症）治療市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場細分：依類型

  • 人工唾液/唾液替代品
  • 唾液促效劑

第7章：市場區隔：依藥物類型

  • 場外交易
  • 處方

第8章：市場區隔：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第10章：SWOT分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • 3M Company
    • Biotene (GSK plc)
    • Parnell Pharmaceuticals Inc.
    • Quest Products LLC
    • Saliwell Ltd
    • Sun Pharmaceutical Industries Limited
    • West-Ward Pharmaceutical (Hikma Pharmaceuticals plc)
Product Code: SR112025A6439

The global xerostomia (dry mouth disease) therapeutics market size was valued at USD 763.03 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 1,007.31 Million by 2033, exhibiting a CAGR of 2.98% from 2025-2033. North America currently dominates the market, holding a market share of over 36.8% in 2024, attributed to a well-established healthcare system, increased disease understanding, and growing incidence of dry mouth due to the elderly population and medications.

The xerostomia (dry mouth disease) therapeutics market expands due to rising incidence of dry mouth conditions, involving Sjogren's syndrome, diabetes, and radiation therapy for cancer patients. The effective treatment demand is witnessing a notable increase with lung cancer and an aging population. Additionally, healthcare professionals alongside patients are increasingly aware of dry mouth disease which drives their pursuit of therapeutic solutions. Moreover, improved drug formulations, including secretagogues and saliva substitutes, profilerating the market forward as these new formulations provide better effectiveness and comfort to patients. Technological advances in drug delivery systems with emphasis on personalized medicine also contribute to the market's growth.

In the United States, the xerostomia therapeutics market is growing with a high incidence of risk factors like aging, diabetes, and cancer therapy, especially head and neck radiation. The increasing use of targeted therapies and technological advancements in over-the-counter products are offering increased treatment choices for patients. For instance, as per industry reports, researchers from University of Wisconsin School of Medicine Public Health, in partnership with PACT, is performing a clinical trial to explore the potential of using a patient's own enhanced stem cells to improve salivary gland function in Sjogren's disease. This innovative approach involves extracting stem cells from the patient's bone marrow, activating them, and injecting them into the salivary glands. Furthermore, as the understanding of xerostomia's impact on health continues to evolve, demand for effective and accessible treatments in the U.S. is expected to rise steadily.

Xerostomia (Dry Mouth Disease) Therapeutics Market Trends:

Advancements in Salivary Stimulant Formulations

The xerostomia therapeutics market has some of the most significant advancements in the formulation of salivary stimulants. The demand for prolonged and effective treatment is, however, driving these changes. Most of the classical saliva substitutes provide only temporary relief, forcing researchers to seek newer or innovative drug delivery methods like mucoadhesive formulations, sustained-release gels, and nanoparticle-based therapies. Companies have also turned their attention to plant-derived compounds or regenerative medicine approaches to stimulate rather than replace this natural saliva production capability. Biologics are being developed targeting salivary gland function, like growth factors and gene therapy, that might offer some long-term benefits. This development improves patient compliance and the efficacy of the treatment through improved moisture retention and decreased frequency of reapplication. Prescription-based formulations with enhanced bioavailability further add to the market's growth. With over 30% of individuals aged 65 and older experiencing dry mouth, there is a growing need for innovative solutions that improve patient compliance and offer sustained relief, a research article stated. As a consequence, the industry is moving away from symptomatic relief products towards therapeutic interventions targeting the cause of dry mouth. This will ensure better patient outcomes.

Growing Adoption of Prescription Therapies Over OTC Products

The market of xerostomia therapeutics is moving away from OTC dry mouth relief products to more prescription-based drugs based on the increasing awareness within the healthcare professional community and the patients' concern for complete long-term management. While OTC products such as artificial saliva sprays, lozenges, or mouth rinses provide mere symptom relief, it does not take into account the root causes of the dryness. On the other hand, prescription medications such as pilocarpine and cevimeline, muscarinic receptor agonists stimulate salivary gland function to produce long-lasting effects. In addition, promising drug candidates for clinical development involve enhancement of saliva flow and glandular regeneration that positions prescription treatments as a more viable option. The healthcare provider has increasingly become recommending prescription treatments to patients who suffer from chronic xerostomia secondary to Sjogren's syndrome, radiation therapy, or polypharmacy-induced dryness. This shift is expected to fuel market growth as pharmaceutical companies continue investing in the development of targeted treatments with improved efficacy and safety profiles. Studies suggest that up to 73.4% of patients undergoing chemotherapy report experiencing xerostomia, with the prevalence rising to 90% among those receiving radiation therapy for head and neck cancers. This trend is driving the adoption of prescription-based treatments targeting the underlying pathology.

Rising Prevalence of Xerostomia Due to Chronic Diseases and Medications

The principal reason for the rising rate of xerostomia cases is the increased number of chronic diseases and side effects from medication. Diseases like diabetes, Sjogren's syndrome, and other autoimmune diseases have a direct impact on salivary glands, causing symptoms of xerostomia to be felt for long durations. Similarly, cancer treatments through radiation therapy and chemotherapy often damage salivary glands, thereby resulting in xerostomia as a common side effect in cancer patients. Studies indicate that xerostomia affects 13-17% of the general population, with prevalence rates rising to 30-40% among the elderly due to polypharmacy. The widespread use of medications such as antihypertensives, antidepressants, and opioids further contributes to the rising number of cases, with over 400 commonly prescribed drugs known to cause dry mouth as a side effect. Demand for effective remedies against xerostomia will increase among the aging globe and the constantly growing burden of chronic diseases. As such, pharmaceutical companies are coming forward with the drugs that can offer symptomatic relief and address the underlying cause of dry mouth. The rising number of patients, thus, represents an important area for innovation and growth in the xerostomia therapeutics market.

Xerostomia (Dry Mouth Disease) Therapeutics Industry Segmentation:

Analysis by Type:

  • Artificial Saliva/Saliva Substitutes
  • Salivary Stimulants

Artificial saliva/saliva substitutes lead the market with around 65.7% of market share in 2024. due These products provide moisture, lubrication, and relief from dry mouth symptoms, improving patients' comfort and quality of life. Available in various forms, such as sprays, gels, and lozenges, artificial saliva products help alleviate discomfort caused by conditions like Sjogren's syndrome or medication-induced xerostomia. Their widespread use in both clinical settings and over-the-counter offerings, along with ongoing advancements in formulation, continues to drive demand, positioning them as a key treatment option for dry mouth management.

Analysis by Drug Type:

  • OTC
  • Prescription

OTC leads the market in 2024, driven by consumer preference for easily accessible, non-prescription solutions. OTC treatments, including mouthwashes, lozenges, gels, and sprays, offer immediate relief from dry mouth symptoms and are widely available in pharmacies and online. The growing trend of self-management and the increasing awareness of xerostomia contribute to the popularity of OTC products. Additionally, their affordability and convenience make them a preferred choice for patients seeking to manage mild to moderate cases of dry mouth without the need for a healthcare provider's prescription.

Analysis by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Retail pharmacy leads the market with around 38.5% of market share in 2024, due to their wide accessibility and convenience for consumers. Patients can easily obtain over-the-counter (OTC) products such as mouthwashes, lozenges, and gels, which are commonly used to manage dry mouth symptoms. The growing preference for self-management of xerostomia, along with the increasing number of retail pharmacy chains globally, has bolstered this segment. Retail pharmacies also benefit from strong relationships with pharmaceutical companies, enabling them to stock a diverse range of therapeutics. Additionally, their ability to provide personalized advice and quick access further drives their dominance in the market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 36.8%, driven by a high prevalence of dry mouth conditions, advanced healthcare infrastructure, and significant investments in research and development. The region's large aging population, particularly in the U.S., contributes to the rising incidence of xerostomia, often linked with medication use, autoimmune diseases, and radiation therapy for cancer treatment. For instance, industry reports state that the U.S. population aged 65 plus is projected to grow from 58 million in 2022 to 82 million by 2050, increasing from 17% to 23% of the total population. Additionally, the presence of key pharmaceutical companies, a robust pipeline of therapeutic products, and favorable reimbursement policies further support market growth. North America's demand for innovative treatments and patient-centered care strategies ensures its leadership in this market.

Key Regional Takeaways:

United States Xerostomia (Dry Mouth Disease) Therapeutics Market Analysis

In 2024, United States accounted for 88.6% of the market share in North America. The U.S. Xerostomia (Dry Mouth Disease) therapeutics market is growing due to the increasing number of chronic patients, such as diabetes and Sjogren's syndrome, among others. According to CDC, in 2023, about 37.3 million Americans had diagnosed diabetes, accounting for a big portion of individuals with dry mouth. Moreover, the growing need for prescription dry mouth treatments by cancer patients after radiation therapy enhances the demand. New saliva substitutes, oral sprays, and regenerative therapies are creating advanced treatment avenues. Developed healthcare system in the United States ensures increased accessibility to xerostomia treatments for patients. Major pharmaceutical giants, GlaxoSmithKline and Colgate-Palmolive, are looking for expansion in their portfolios of oral health care. Government-aided health care, Medicare, and Medicaid continue to make treatments affordable for patients, and increasing awareness programs also facilitate timely diagnosis and adherence to treatments. The integration of AI in dental healthcare is also improving patient outcomes, positioning the U.S. as a key market for xerostomia therapeutics.

Europe Xerostomia (Dry Mouth Disease) Therapeutics Market Analysis

The European Xerostomia therapeutics market is experiencing growth due to the aging population and increasing diabetes and autoimmune cases. It is estimated by the World Health Organization (WHO) that about 74 million adults and 300,000 children and adolescents in Europe are suffering from diabetes, the greatest risk factor for xerostomia. In addition, an increase in the number of cancer patients treated using radiation therapy causes a boosted demand for saliva substitutes and prescription treatments. Germany and France lead the market in terms of adoption since their healthcare systems are well established. Unilever and Reckitt companies are taking a challenge to apply innovative oral hydration solutions and prescription medicines. European Union rules promoting access to advanced patient therapies support market expansion, as increased research and development result in novel treatment solutions, positioning Europe as a central market for xerostomia therapeutics.

Asia Pacific Xerostomia (Dry Mouth Disease) Therapeutics Market Analysis

Asia Pacific is experiencing a huge growth in the Xerostomia therapeutics market due to the increasing diabetic population and the increasing awareness of oral health. The International Diabetes Federation (IDF) states that by 2023, China had around 140 million people living with diabetes, significantly contributing to the prevalence of dry mouth. The elderly population in Japan, at about 29% of the total population, further fuels the demand for xerostomia treatments. The potential for the market increases in addition to government healthcare services in the form of various schemes, such as Ayushman Bharat by India, which encourages oral health awareness. Herbal and natural saliva substitutes are emerging nowadays, especially in countries like China and India. Pharmaceutical companies like Sun Pharma and Takeda are increasing their market presence both domestically and internationally. The increasing use of digital healthcare platforms is enhancing access to treatment, making Asia Pacific a key region for market growth.

Latin America Xerostomia (Dry Mouth Disease) Therapeutics Market Analysis

The Latin American Xerostomia therapeutics market is growing because of increased investments in healthcare and the rising prevalence of chronic diseases. According to an industry report, Brazil's healthcare spending has reached USD 161 billion in 2023, with a significant share spent on oral health care, as per reports. Increasing cases of xerostomia caused by diabetes and cancer treatments are pushing the demand for therapeutic solutions. Brazil and Mexico have the largest market share in that region, therefore, are shifting their focus toward increasing prescription-only dry mouth therapies. According to an industry report, more than 1.7 million aesthetic and dental operations were conducted within Mexico in the year 2023, contributing to the augmented demand for oral hydration solutions. Multinational companies are coming together with regional firms to create advanced saliva substitutes and prescription-only medications. The market growth in the region is likely to be sustained by government-backed healthcare programs and rising private investments in oral health care.

Middle East and Africa Xerostomia (Dry Mouth Disease) Therapeutics Market Analysis

Middle East and Africa Xerostomia therapeutics market is also witnessing growth in this region as there is growing healthcare investment coupled with a higher incidence of chronic diseases such as diabetes. As per the UAE government data, the federal healthcare budget for 2022 was USD 1.16 billion. It allocated most of the healthcare budget to oral healthcare services. Diabetes is quite prevalent in this region, particularly in the gulf countries. The demand for prescription medication, such as pilocarpine, in Saudi Arabia is on the rise due to an incidence rate of over 18% for diabetes. In South Africa, increasing production by pharmaceutical companies contributes to increased oral hydration solution availability. Dental and oral healthcare awareness is further bolstering the market within the region. Investments in health infrastructure, along with collaborations between local and international pharmaceutical companies, are likely to boost the growth of advanced treatments for xerostomia.

Competitive Landscape:

The competition among the established pharmaceutical firms and emerging biotechnology companies drives the market for xerostomia (dry mouth disease) therapeutics. The key players are focused on the development and commercialization of some products, including saliva substitutes, secretagogues, and therapies focusing on the underlying causes of xerostomia. Companies are putting in substantial investments to create new drug formulations and sophisticated delivery systems to fill unmet needs in patient care. Besides, firms often take on strategic partnerships and acquisitions to base their portfolios of products and enhance market reach. Competition is further influenced by important aspects, such as regulatory approvals, pricing strategies, and clinical effectiveness. For instance, in December 2024, MeiraGTx Holdings announced that they received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for their product AAV2-hAQP1 for the treatment of Grade 2/3 radiation-induced xerostomia. This designation highlights the therapy's potential to address unmet needs, expedite development, and enhance patient outcomes for those affected by radiation-induced dry mouth.

The report provides a comprehensive analysis of the competitive landscape in the xerostomia (dry mouth disease) therapeutics market with detailed profiles of all major companies, including:

  • 3M Company
  • Biotene (GSK plc)
  • Parnell Pharmaceuticals Inc.
  • Quest Products LLC
  • Saliwell Ltd
  • Sun Pharmaceutical Industries Limited
  • West-Ward Pharmaceutical (Hikma Pharmaceuticals plc)

Key Questions Answered in This Report

  • 1.How big is the xerostomia (dry mouth disease) therapeutics market?
  • 2.What is the future outlook of xerostomia (dry mouth disease) therapeutics market?
  • 3.What are the key factors driving the xerostomia (dry mouth disease) therapeutics market?
  • 4.Which region accounts for the largest xerostomia (dry mouth disease) therapeutics market share?
  • 5.Which are the leading companies in the global xerostomia (dry mouth disease) therapeutics market?q

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Xerostomia (Dry Mouth Disease) Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Artificial Saliva/Saliva Substitutes
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Salivary Stimulants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 OTC
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Prescription
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 3M Company
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Biotene (GSK plc)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Parnell Pharmaceuticals Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Quest Products LLC
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Saliwell Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Sun Pharmaceutical Industries Limited
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 West-Ward Pharmaceutical (Hikma Pharmaceuticals plc)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio

List of Figures

  • Figure 1: Global: Xerostomia Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Xerostomia Therapeutics Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Xerostomia Therapeutics Market: Breakup by Drug Type (in %), 2024
  • Figure 6: Global: Xerostomia Therapeutics Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Xerostomia Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Xerostomia Therapeutics (Artificial Saliva/Saliva Substitutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Xerostomia Therapeutics (Artificial Saliva/Saliva Substitutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Xerostomia Therapeutics (Salivary Stimulants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Xerostomia Therapeutics (Salivary Stimulants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Xerostomia Therapeutics (OTC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Xerostomia Therapeutics (OTC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Xerostomia Therapeutics (Prescription) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Xerostomia Therapeutics (Prescription) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Xerostomia Therapeutics (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Xerostomia Therapeutics (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Xerostomia Therapeutics (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Xerostomia Therapeutics (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Xerostomia Therapeutics (Online Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Xerostomia Therapeutics (Online Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: North America: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: North America: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: United States: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: United States: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Canada: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Canada: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Asia-Pacific: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Asia-Pacific: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: China: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: China: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Japan: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Japan: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: India: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: India: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: South Korea: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: South Korea: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Australia: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Australia: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Indonesia: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Indonesia: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Others: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Others: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Europe: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Europe: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Germany: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Germany: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: France: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: France: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: United Kingdom: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: United Kingdom: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Italy: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Italy: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Spain: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Spain: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Russia: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Russia: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Others: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Others: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Latin America: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Latin America: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Brazil: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Brazil: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Mexico: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Mexico: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Middle East and Africa: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Middle East and Africa: Xerostomia Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 70: Middle East and Africa: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Global: Xerostomia Therapeutics Industry: SWOT Analysis
  • Figure 72: Global: Xerostomia Therapeutics Industry: Value Chain Analysis
  • Figure 73: Global: Xerostomia Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Xerostomia Therapeutics Market: Key Industry Highlights 2024 and 2033
  • Table 2: Global: Xerostomia Therapeutics Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Xerostomia Therapeutics Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Xerostomia Therapeutics Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Xerostomia Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Xerostomia Therapeutics Market: Competitive Structure
  • Table 7: Global: Xerostomia Therapeutics Market: Key Players